Nadofaragene firadenovec
Adstiladrin (nadofaragene firadenovec) is a gene pharmaceutical. Nadofaragene firadenovec was first approved as Adstiladrin on 2022-12-16.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Adstiladrin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Nadofaragene firadenovec
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Adstiladrin | nadofaragene firadenovec-vncg | Ferring Pharmaceuticals A/S | N-125700 RX | 2022-12-16 | 1 products |
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
nadofaragene firadenovec, Adstiladrin, Ferring Pharmaceuticals A/S | |||
| 2034-12-16 | Reference product excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malignant mesothelioma | D000086002 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NADOFARAGENE FIRADENOVEC |
| INN | nadofaragene firadenovec |
| Description | Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer. It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy.
|
| Classification | Gene |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990041 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 0OOS09O1FH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 69 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more